Ken Hsu is scientific founder of a new startup biotech company that launched this week with $56M in seed financing. Hyku Biosciences aims to develop covalent oncology drugs based on advancing Hsu’s sulfur–triazole exchange (SuTEx) chemistry.
https://www.hykubiosciences.com/news-media/press-release-9-19-23
